VacZine Analytics  
MarketVIEW: Group B Streptococcus

Updated May 2014

Group B beta streptococci (GBS) or Streptococcus agalactiae is an encapsulated Gram-positive coccus capable of producing a range of diseases in humans of all age ranges. In the neonate, the bacterium can cause severe life threatening sepsis and meningitis (early and late onset disease) due to ascending spread of GBS from the birth canal of colonized females (~30% of total) who are typically asymptomatic.

A number of manufacturers have considered the development of a GBS prophylatic vaccine. Such a vaccine may be offered to adolescents to prevent neonatal disease after pregnancy later in life or for older women planning or during a pregnancy. Other possible uses might be in immunocompromised/elderly individuals who are hospitalized and reside in long-term care facilities.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of new Group B Streptococcus vaccines across Western and ROW markets to 2035. The model contains value ($ m) and volume (mio doses) predictions for each country/risk group and discusses current dynamics in disease incidence and competitor activity. A review of the Novartis/GSK trivalent maternal strategy is also covered.

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV008 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20% (from January 2011) Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2014 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains